Physician profile
Anna Pruitt
NPI 1023057676
$1,888.26
in general payments reported to CMS, 2019-2025
21 companies · $419 in 2025
The $419 reported for 2025 was more than what 91% of Pediatrics providers received nationally (typical 2025 total: $96.93).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $132 · 2020: $226 · 2021: $202 · 2022: $308 · 2023: $262 · 2024: $340 · 2025: $419.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,020.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,020.27 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Supernus Pharmaceuticals, INC. | $802.36 | 2021-2025 | Qelbree, Qelbree |
| Takeda Pharmaceuticals U.S.A., INC. | $127.82 | 2020-2022 | |
| Kowa Pharmaceuticals America, INC. | $117.50 | 2024-2025 | Zoryve |
| Glaxosmithkline, LLC. | $85.52 | 2019-2023 | Bexsero |
| Corium, LLC | $84.46 | 2021-2022 | |
| Ironshore Pharmaceuticals INC. | $82.16 | 2019-2022 | |
| Emd Serono, INC. | $74.77 | 2020 | |
| Merck Sharp & Dohme LLC | $66.84 | 2023-2025 | Gardasil 9, Vaxneuvance, M-M-R II |
| Seqirus USA INC | $66.22 | 2023-2025 | Flucelvax, Flucelvax Quadrivalent |
| Vertical Pharmaceuticals, LLC | $61.56 | 2019 | |
| Tris Pharma INC | $56.91 | 2019-2020 | |
| Sobi, INC | $46.34 | 2020-2022 | |
| Sanofi Pasteur INC. | $36.27 | 2019-2021 | |
| Neuraxis, INC. | $35.15 | 2024 | |
| Kyowa Kirin, INC. | $27.45 | 2025 |
Show all 21 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Alexion Pharmaceuticals, INC. | $27.24 | 2025 | Strensiq |
| Astrazeneca Pharmaceuticals LP | $23.04 | 2024 | Flumist Quadrivalent |
| Abbott Laboratories | $22.51 | 2025 | Freestyle Libre 3 |
| Adlon Therapeutics L.P. | $20.15 | 2020 | |
| Pfizer INC. | $12.90 | 2023 | |
| Biofrontera INC. | $11.09 | 2023 | Ameluz, Xepi, Bf-Rhodoled |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Anna Pruitt listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.